Axl inhibitors

By optimizing the compound structure of Axl kinase inhibitors, the problems of insufficient activity and poor pharmacokinetic properties of existing compounds have been solved, resulting in more efficient disease treatment.

CN117412953BActive Publication Date: 2026-11-17WIGEN BIOMEDICINE TECH (SHANGHAI) CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202280034595.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-12
Filing Date
2022-05-11
Publication Date
2026-11-17
Estimated Expiration
2042-05-11

AI Technical Summary

Technical Problem

Existing Axl kinase inhibitors suffer from insufficient activity and poor pharmacokinetic properties in clinical applications, making them difficult to effectively treat a variety of diseases, including cancer, vascular diseases, and kidney diseases.

Method used

Compounds of formulas (1)-(4) and their isomers, pharmaceutically acceptable salts, hydrates or solvates were developed, and the Axl inhibitory activity and pharmacokinetic properties were improved by synthesizing and optimizing the structure of these compounds.

Benefits of technology

This improved the Axl inhibitory activity and pharmacokinetic properties of the compound, enhanced its therapeutic effect on related diseases, and provided a more efficient treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117412953B_ABST
    Figure CN117412953B_ABST
Patent Text Reader

Abstract

A class of Axl inhibitors. Specifically, it relates to a novel compound as shown in formulas (1), (2), (3), (4) and / or a pharmaceutically acceptable salt thereof, as well as compositions containing compounds as shown in formulas (1), (2), (3), (4) and / or pharmaceutically acceptable salts thereof, methods of preparation thereof, and their use as Axl inhibitors in the preparation of antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese application CN202110518860.4, filed on May 12, 2021. The full text of the aforementioned Chinese application is incorporated herein by reference. Technical Field

[0002] This invention relates to the field of medicinal chemistry, and more specifically, to novel compounds with Axl kinase inhibitory activity, methods for their preparation, and the use of such compounds in the preparation of antitumor drugs. Background Technology

[0003] Receptor tyrosine kinases (RTKs) sense extracellular signals, activating cytoplasmic and nuclear signal transduction pathways to regulate cell survival, growth, differentiation, adhesion, and migration. Aberrant expression or activation of RTKs is involved in cancer cell transformation, tumor formation, and metastasis. Tyrosine kinase inhibitors are already used clinically to treat cancer.

[0004] Axl is a member of the TAM subfamily of RTK kinases. Other members of this family include MER and Tyro-3. TAM family kinases contain an extracellular domain that binds to a ligand, a transmembrane domain that mediates signal transduction, and a conserved intracellular kinase domain. Axl and MER are overexpressed in various leukemia cells and multiple solid tumor cells, promoting cancer cell survival, metastasis, and drug resistance. Besides cancer cells, AXL is expressed in vascular epithelial cells and smooth cells in the tumor microenvironment (Korshunov et al., Circ. Res. 2006, 98, 1446), as well as in various immune cells including macrophages, dendritic cells, and natural killer cells, promoting angiogenesis, immunosuppression, and immune escape of tumor cells (Sharif et al., J. Exp. Med. 2006, 203, 1891; Rothlin et al., Cell. 2007, 131, 1124) (Lu et al., Nature. 1999, 398, 723; Lu & Lemke, Science. 2001, 293, 306; Prasad et al., Mol. Cell Neurosci. 2006, 3, 96; Shankar et al., J. Neurosci. 2003, 23, 4208). Therefore, AXL participates in tumorigenesis and development through multiple mechanisms.

[0005] Beyond tumors, overactivation of the Axl pathway is involved in vascular diseases induced by dysfunctions in the immune system, platelet function, vascular calcification, and thrombin-induced vascular smooth muscle cells, as well as pathological processes such as acute and chronic glomerulonephritis, diabetic nephropathy, and chronic allogeneic transplant rejection. Axl inhibitors are expected to provide therapeutic benefits for a variety of diseases, including cancer (including solid tumors such as carcinoma and sarcoma, leukemia, and lymphoma), vascular diseases (including but not limited to thrombosis, atherosclerosis, and restenosis), kidney diseases (including but not limited to acute and chronic glomerulonephritis, diabetic nephropathy, and transplant rejection), and serious diseases with consequences induced by disordered angiogenesis (including but not limited to diabetic retinopathy, retinopathy, psoriasis, rheumatoid arthritis, atherosclerosis, Kaposi's sarcoma, and hemangioma).

[0006] Therefore, developing small molecule inhibitors of highly active Axl kinase has important clinical value.

[0007] WO2015012298A1 reports compound A (Example 5 in WO2015012298A1) which has Axl inhibitory activity. A phase I clinical trial of this compound for the treatment of osimertinib-resistant non-small-cell lung cancer is ongoing.

[0008] Summary of the Invention

[0009] This invention provides compounds of formulas (1)-(4) or their isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates:

[0010]

[0011] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a diluent and / or an excipient, and the compound shown in the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.

[0012] Another object of the present invention is to provide the use of the compounds shown in the present invention, or their isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, or the pharmaceutical compositions thereof, in the preparation of medicaments for the treatment, regulation or prevention of diseases related to Axl protein.

[0013] Another object of the present invention is to provide a method for treating, modulating or preventing diseases related to Axl protein, comprising administering to a subject a therapeutically effective amount of the compound shown in the present invention, or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition thereof.

[0014] Through the synthesis and careful study of various new compounds involving Axl inhibition, the inventors discovered that among the compounds shown in formulas (1), (2), (3), and (4), compound (1) exhibits unexpected improvements in PK properties and enhanced Axl inhibitory activity compared to compound A.

[0015] It should be understood that the foregoing general description of the invention and the following detailed description are exemplary and illustrative, and are intended to provide further explanation of the claimed invention.

[0016] Further forms of the compound

[0017] "Pharmaceutical acceptable" here means that a substance, such as a carrier or diluent, will not destroy the biological activity or properties of a compound and is relatively non-toxic. For example, when given to an individual, a substance will not cause unwanted biological effects or interact with any of its components in a harmful manner.

[0018] The term "pharmaceutically acceptable salt" refers to a form of a compound that does not cause significant irritation to the administered organism and does not diminish the compound's biological activity and properties. In some specific aspects, pharmaceutically acceptable salts are obtained by reacting the compounds shown in this invention with acids, such as inorganic acids like hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, and carbonic acid; organic acids like formic acid, acetic acid, propionic acid, oxalic acid, trifluoroacetic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid; and acidic amino acids like aspartic acid and glutamic acid.

[0019] It should be understood that references to pharmaceutically acceptable salts include solvent-added forms or crystalline forms, especially solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric solvents and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. When the solvent is water, a hydrate is formed, or when the solvent is ethanol, an alcohol is formed. Solvates of the compounds shown in this invention are readily prepared or formed according to the methods described herein. For example, hydrates of the compounds shown in this invention are readily prepared by recrystallization from a mixture of water and an organic solvent, the organic solvents used including, but not limited to, tetrahydrofuran, acetone, ethanol, or methanol. Furthermore, the compounds mentioned herein can exist in both solvated and non-solvated forms. In summary, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the non-solvated form.

[0020] In other specific embodiments, the compounds shown in this invention are prepared in various forms, including but not limited to amorphous, pulverized, and nano-particle forms. Furthermore, the compounds shown in this invention include crystalline forms and can also be polymorphic. Polymorphs comprise different lattice arrangements of the same elemental composition of the compound. Polymorphs typically have different X-ray diffraction spectra, infrared spectra, melting points, densities, hardness, crystal forms, optical and electrical properties, stability, and solubility. Different factors such as recrystallization solvents, crystallization rates, and storage temperatures may cause a single crystal form to dominate.

[0021] In another aspect, the compounds shown in this invention may possess chiral centers and / or axial chirality, and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers, as well as cis-trans isomers. Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of this invention. This invention implies the inclusion of all such isomeric forms of these compounds.

[0022] The compounds of this invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium. 3 H), Iodine-125 ( 125 I) and C-14 14 C). For example, deuterium can be used to replace hydrogen atoms to form deuterated compounds. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs generally have advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged drug half-life in vivo. All isotopic variations of the compounds of this invention, regardless of radioactivity, are included within the scope of this invention.

[0023] the term

[0024] Unless otherwise specified, the terms used in this application, including the specification and claims, are defined as follows. It must be noted that in the specification and appended claims, unless otherwise clearly indicated, the singular form "a" includes the plural meaning. Unless otherwise specified, conventional methods such as mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology are used. In this application, unless otherwise specified, "or" or "and" refers to "and / or".

[0025] Specific pharmaceutical and medical terminology

[0026] The term “acceptable,” as used herein, means that a prescription component or active ingredient does not have an excessively harmful effect on health for general therapeutic purposes.

[0027] The terms “treatment,” “treatment process,” or “therapy” as used herein include alleviating, suppressing, or improving symptoms or conditions of a disease; suppressing the development of complications; improving or preventing underlying metabolic syndromes; suppressing the development of a disease or symptom, such as controlling the progression of a disease or condition; reducing a disease or symptom; alleviating a disease or symptom; reducing complications arising from a disease or symptom; or preventing or treating signs arising from a disease or symptom. As used herein, a compound or pharmaceutical composition, when administered, may improve a disease, symptom, or condition, particularly by improving its severity, delaying its onset, slowing its progression, or reducing its duration. Whether administered regularly or intermittently, continuously or intermittently, it may be attributable to or related to the administration.

[0028] "Active ingredient" refers to the compounds shown in this invention, as well as pharmaceutically acceptable inorganic or organic salts of the compounds shown in this invention. The compounds of this invention may contain one or more asymmetric centers (chiral or axially chiral), and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers. The asymmetric centers that may exist depend on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of this invention. This invention means including all such isomeric forms of these compounds.

[0029] The terms “compound,” “composition,” “agent,” or “medicine or medicament” may be used interchangeably here, and all refer to a compound or composition that, when applied to an individual (human or animal), can induce a desired pharmaceutical and / or physiological response through local and / or systemic action.

[0030] The term “administered, administering, or administration” here refers to the direct application of the compound or composition described herein, or the application of a prodrug, derivative, or analog of the active compound.

[0031] While the numerical ranges and parameters used to define the broader scope of this invention are approximate values, the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "approximately" may mean that the actual value falls within the acceptable standard error of the mean, as determined by those skilled in the art. Except for experimental examples, or unless explicitly stated otherwise, it is understood that all ranges, quantities, values, and percentages used herein (e.g., to describe material usage, duration, temperature, operating conditions, quantity ratios, and others similar) are modified with "approximately". Therefore, unless otherwise stated, the numerical parameters disclosed in this specification and the accompanying claims are approximate values ​​and are subject to change as needed. At a minimum, these numerical parameters should be understood as the indicated significant digits and values ​​obtained using general rounding.

[0032] Unless otherwise defined in this specification, scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art. Furthermore, unless conflicting with the context, singular nouns used herein include their plural forms, and vice versa.

[0033] Therapeutic uses

[0034] This invention provides that the use of compounds or pharmaceutical compositions shown in this invention is generally available for inhibiting Axl kinase, and therefore can be used to treat one or more conditions associated with Axl kinase activity. Therefore, in some embodiments, this invention provides a method for treating Axl kinase-mediated conditions, the method comprising the step of administering the compounds of this invention, or pharmaceutically acceptable compositions thereof, to a patient in need.

[0035] Cancers that can be treated with the compounds of this invention include, but are not limited to, hematologic malignancies (leukemia, lymphoma, myeloma including multiple myeloma, myelodysplastic syndrome and myeloproliferative syndrome) and solid tumors (cancers such as prostate, breast, lung, colon, pancreas, kidney, ovary and soft tissue cancers and osteosarcoma, as well as stromal tumors).

[0036] route of administration

[0037] The compounds of this invention and their pharmaceutically acceptable salts can be formulated into various preparations, comprising, within a safe and effective range, the compounds of this invention or their pharmaceutically acceptable salts and pharmacologically acceptable excipients or carriers. "Safe and effective range" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. The safe and effective range of the compound is determined based on the age, condition, and duration of treatment of the patient.

[0038] "Pharmaceutically acceptable excipients or carriers" refers to one or more compatible solid or liquid fillers or gelling substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with and with the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as... Wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0039] When applying the compounds of this invention, they can be administered orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), or topically.

[0040] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.

[0041] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compound from such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the excipients described above.

[0042] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0043] In addition to these inert diluents, the composition may also contain auxiliaries such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances.

[0044] In addition to the active compound, the suspension may contain suspending agents such as ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0045] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.

[0046] Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be necessary.

[0047] The compounds of this invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using the pharmaceutical composition, a safe and effective amount of the compound of this invention is applied to the mammal (such as a human) requiring treatment, wherein the dose administered is a pharmaceutically considered effective dose. For a person weighing 60 kg, the daily dose is typically 1–2000 mg, preferably 50–1000 mg. Of course, the specific dosage should also consider factors such as the route of administration and the patient's health condition, which are all within the scope of a skilled physician's expertise.

[0048] The features mentioned above in this invention, or the features mentioned in the embodiments, can be combined arbitrarily. All features disclosed in this specification can be used in any compositional form, and each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the disclosed features are merely general examples of equivalent or similar features. Detailed Implementation

[0049] The following description will elaborate on the specific aspects, characteristics, and advantages of the aforementioned compounds, methods, and pharmaceutical compositions, making the content of this invention readily apparent. It should be understood that the detailed descriptions and examples described below are specific embodiments and are for reference only. After reading this description, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by this application.

[0050] In all embodiments, 1 H-NMR was recorded using a Varian Mercury 400 NMR spectrometer, and chemical shifts are expressed as δ (ppm). Unless otherwise specified, the silica gel used for separation was 200-300 mesh, and all eluent ratios were by volume.

[0051] The following abbreviations are used in this invention: CDCl3 represents deuterated chloroform; EtOAc represents ethyl acetate; Hexane represents n-hexane; HPLC represents high performance liquid chromatography; MeCN represents acetonitrile; DCM represents dichloromethane; DIPEA represents diisopropylethylamine; DMF represents N,N-dimethylformamide; DMAP represents 4-(dimethylamino)pyridine; DMSO represents dimethyl sulfoxide; HATU represents O-(7-azabenzotriazol-1-yl)-NNN′N′-tetramethylurea hexafluorophosphate; hr represents hours; min represents minutes; K2CO3 represents potassium carbonate; min represents minutes; MeOH represents methanol; MS represents mass spectrometry; NMR represents nuclear magnetic resonance; Pd / C represents palladium on carbon; POCl3 represents phosphorus oxychloride; TEA represents triethylamine; TLC represents thin-layer chromatography.

[0052] Example 1: Synthesis of Compound 1

[0053]

[0054] Step 1: Synthesis of compound int_1-2:

[0055]

[0056] Int_1-1 (200 mg, 0.951 mmol), DMF (5 mL), anhydrous potassium carbonate (5.92 g, 42.9 mmol), and fluoroiodomethane (229 mg, 1.43 mmol) were added to a 100 mL single-necked flask. After purging the mixture with argon, the mixture was stirred at room temperature for 16 hours. After the reaction was confirmed to be complete by LC-MS, ethyl acetate (10 mL) and water (10 mL) were added to the mixture. The mixture was stirred and separated. The aqueous phase was extracted again with ethyl acetate (10 mL). The combined organic phases were washed twice with saturated sodium chloride solution (10 mL * 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a light brown solid product (211 mg, yield: 90.5%).

[0057] ESI-MS m / z: 242 [M+H] +

[0058] Step 2: Synthesis of compound int_1-3:

[0059]

[0060] In a 50 mL single-necked flask, int_1-2 (211 mg, 0.86 mmol), DMF (5 mL), DIPEA (1.5 mL), and 6-nitropyridine-3-ol (121 mg, 0.86 mmol) were added. After purging the mixture with argon, the temperature was raised to 100 °C and stirred for 72 hours. LC-MS analysis showed the reaction was nearly complete. Then, ethyl acetate (10 mL) and water (10 mL) were added to the mixture, and the mixture was stirred and separated. The aqueous phase was extracted again with ethyl acetate (10 mL). The combined organic phases were washed successively with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oily substance (228 mg, yield: 76%). ESI-MS m / z: 346 [M+H] +

[0061] Step 3: Synthesis of compounds int_1-4:

[0062]

[0063] In a 100 mL single-necked flask, int_1-3 (228 mg, crude product, 0.66 mmol), MeOH (10 mL), DCM (1 mL), and 10% palladium on carbon (50 mg, wet = 55%) were added. After purging with hydrogen three times, the mixture was stirred at room temperature and atmospheric pressure for hydrogenation. After 72 hours, LC-MS analysis showed that the reaction was complete. The mixture was filtered with diatomaceous earth as an aid, and the filtrate was concentrated to obtain the product (220 mg, yield: 100%).

[0064] ESI-MS m / z: 316 [M+H] +

[0065] Step 4: Synthesis of Compound 1:

[0066]

[0067] Add int_1-4 (93 mg, 0.295 mmol), DMF (5 mL), DIPEA (114 mg, 0.885 mmol), HATU (170 mg, 0.442 mmol), and int_1-5 (84 mg, 0.295 mmol) to a 50 mL single-necked flask. After purging the mixture with argon, heat to 60 °C and stir for 4 hours. After the reaction was basically complete as detected by LC-MS, the mixture was purified by preparative LC-MS to obtain the product (16 mg, yield: 9.3%).

[0068] 1 H NMR(400MHz,Chloroform-d)δ11.94(s,1H),9.33(s,1H),8.55(d,J=5.3Hz,1H ),8.50(d,J=9.0Hz,1H),8.21(d,J=2.8Hz,1H),7.92(s,1H),7.66–7.54(m,4H ),7.48(s,1H),7.27(d,J=1.7Hz,1H),7.25(s,1H),6.44(d,J=5.3Hz,1H),5.9 8(s,1H),5.84(s,1H),4.05(s,3H),2.65–2.54(m,4H),2.12(q,J=6.3Hz,2H).

[0069] ESI-MS m / z: 581 [M+H] +

[0070] Example 2: Synthesis of Compound 2

[0071]

[0072] Step 1: Synthesis of compound int_2-2:

[0073]

[0074] Int_2-1 (200 mg, 0.951 mmol), DMF (5 mL), anhydrous potassium carbonate (5.92 g, 42.9 mmol), and fluoroiodomethane (229 mg, 1.43 mmol) were added to a 100 mL single-necked flask. After purging the mixture with argon, the mixture was stirred at room temperature for 16 hours. After the reaction was confirmed to be complete by LC-MS, ethyl acetate (10 mL) and water (10 mL) were added to the mixture. The mixture was stirred and separated. The aqueous phase was extracted again with ethyl acetate (10 mL). The combined organic phases were washed twice with saturated sodium chloride solution (10 mL * 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a light brown solid product (208 mg, yield: 90%).

[0075] ESI-MS m / z: 242 [M+H] +

[0076] Step 2: Synthesis of compound int_2-3:

[0077]

[0078] Int2-2 (208 mg, 0.86 mmol), DMF (5 mL), DIPEA (1.5 mL), and 6-nitropyridine-3-ol (121 mg, 0.86 mmol) were added to a 50 mL single-necked flask. After purging the mixture with argon, the temperature was raised to 100 °C and stirred for 72 hours. LC-MS analysis showed the reaction was nearly complete. Ethyl acetate (10 mL) and water (10 mL) were added to the mixture, and the mixture was stirred and separated. The aqueous phase was extracted again with ethyl acetate (10 mL). The combined organic phases were washed successively with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oily substance (220 mg, yield: 76%). ESI-MS m / z: 346 [M+H] +

[0079] Step 3: Synthesis of compound int_2-4:

[0080]

[0081] In a 100 mL single-necked flask, int₂⁻³ (220 mg, crude product, 0.66 mmol), MeOH (10 mL), DCM (1 mL), and 10% palladium on carbon (50 mg, wet = 55%) were added. After purging with hydrogen three times, the mixture was stirred at room temperature and atmospheric pressure for hydrogenation. After 72 hours, LC-MS analysis showed that the reaction was complete. The mixture was filtered with diatomaceous earth as an aid, and the filtrate was concentrated to obtain the product (220 mg, yield: 100%).

[0082] ESI-MS m / z: 316 [M+H] +

[0083] Step 4: Synthesis of Compound 2:

[0084]

[0085] Add int_2-4 (100 mg, 0.317 mmol), DMF (5 mL), DIPEA (114 mg, 0.885 mmol), HATU (170 mg, 0.442 mmol), and int_1-5 (84 mg, 0.295 mmol) to a 50 mL single-necked flask. After purging the mixture with argon, heat to 60 °C and stir for 4 hours. After the reaction was basically complete as detected by LC-MS, the mixture was purified by preparative LC-MS to obtain the product (19 mg, yield: 10.3%).

[0086] 1 H NMR (400MHz, Chloroform-d) δ11.95(s,1H),9.32(s,1H),8.54(d,J=5.3Hz,1H),8.51(d,J=9.0Hz,1H),8.22(d,J=2.8Hz,1H),7.80(s,1H),7.66–7. 54(m,5H),7.27(d,J=1.5Hz,1H),6.50(d,J=5.3Hz,1H),6.00(s,1H),5.87 (s,1H),4.06(s,3H),2.59(dt,J=13.3,6.3Hz,4H),2.11(q,J=6.3Hz,2H).

[0087] ESI-MS m / z: 581 [M+H] + .

[0088] Example 3: Synthesis of Compound 3

[0089]

[0090] Step 1: Synthesis of compound int_3-2:

[0091]

[0092] 40 mL of nitric acid (64%) was added to a 100 mL single-necked flask. 1-fluoro-2,3-dimethoxybenzene (8 g, 51.23 mmol) was added dropwise under ice bath conditions. The mixture was stirred for 15 minutes under ice bath conditions, then allowed to rise to room temperature and stirred for another 15 minutes. After the reaction was complete as monitored by TLC, the reaction mixture was poured into 200 mL of cold water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was then subjected to column chromatography to obtain the target product (6 g, yield: 58%, white solid).

[0093] 1 H NMR (400MHz, Chloroform-d) δ7.68(ddd,J=10.7,2.7,0.8Hz,1H),7.61(t,J=2.2Hz,1H),4.07(dd,J=2.2,0.8Hz,3H),3.96(d,J=0.8Hz,3H).

[0094] Step 2: Synthesis of compound int_3-3:

[0095]

[0096] Int_3-2 (6 g, 29.83 mmol) and 10% palladium on carbon (600 mg, wet = 55%) were suspended in methanol (150 mL) at room temperature. After three purgings with hydrogen, the mixture was stirred overnight at room temperature and atmospheric pressure. LC-MS showed that a large amount of product was formed. The mixture was filtered with diatomaceous earth as an aid, and the filtrate was concentrated to obtain the target product (5 g, 97% yield, gray solid).

[0097] ESI-MS m / z: 172 [M+H] +

[0098] Step 3: Synthesis of compound int_3-5:

[0099]

[0100] Int_3-3 (5.11 g, 29.85 mmol) and int_3-4 (6.46 g, 29.85 mmol) were suspended in ethanol (150 mL) at room temperature. The mixture was stirred under reflux for 1 hour under argon protection. After the reaction was monitored by LC-MS, the mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was separated by column chromatography to obtain the target product (10 g, 98% yield, brown liquid).

[0101] Step 4: Synthesis of compound int_3-6:

[0102]

[0103] 10.2 g (29.88 mmol) of int_3-5 was suspended in 100 mL of diphenyl ether at room temperature, and the mixture was refluxed at 250 °C for 1 hour. The reaction was monitored by LC-MS until completion. After cooling to room temperature, the insoluble residue was collected by filtration to obtain the target product (2.6 g, 30% yield, brown solid). The crude product was used directly in the next reaction step.

[0104] ESI-MS m / z: 296 [M+H] +

[0105] Step 5: Synthesis of compound int_3-7:

[0106]

[0107] INT3-6 (3 g, 10.16 mmol) was suspended in ethanol (20 mL) at room temperature, and sodium hydroxide aqueous solution (4 M, 80 mL) was added. The reaction mixture was stirred at 90 °C for 2 hours. The reaction was monitored by LC-MS until completion. After cooling to room temperature, the pH was adjusted to 1 with concentrated hydrochloric acid. The solid was collected, washed with cold dilute hydrochloric acid, and dried to obtain the target product (2.6 g, yield: 95%, grayish-brown solid). ESI-MS m / z: 268 [M+H] +

[0108] Step 6: Synthesis of compound int_3-8:

[0109]

[0110] int_3-6 (2.6 g, 9.73 mmol) was suspended in diphenyl ether (120 mL) at room temperature and refluxed at 250 °C for 1 hour. The reaction was monitored by LC-MS until it was complete. After cooling to room temperature, the insoluble matter was collected by filtration to obtain the target product (2 g, 92% yield, gray solid).

[0111] ESI-MS m / z: 224 [M+H] +

[0112] Step 7: Synthesis of compound int_3-9:

[0113]

[0114] INT3-8 (1.7 g, 7.62 mmol) was dissolved in phosphine oxychloride (15 mL) at room temperature. The mixture was stirred at 100 °C for 1 hour. The reaction was monitored by LC-MS until completion. Excess phosphine oxychloride was removed by concentration under reduced pressure. The residue was added to a large amount of water and stirred for 10 minutes. The mixture was extracted with DCM, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure. The residue was then subjected to column chromatography to obtain the target product (1.3 g, yield: 61%, gray solid).

[0115] 1 H NMR (400MHz, DMSO-d6) δ8.68(d,J=4.8Hz,1H),7.56(d,J=4.8Hz,1H),7.41(d,J=1.9Hz,1H),3.99(s,3H),3.92(s,3H).

[0116] ESI-MS m / z: 242 [M+H] +

[0117] Step 8: Synthesis of compound int_3-10:

[0118]

[0119] Add int_3-9 (300 mg, 1.24 mmol), int_3-10 (260.7 mg, 1.24 mmol), chlorobenzene (12 mL), and DMAP (227 mg, 1.86 mmol) to a 50 mL single-necked flask. After purging the mixture with argon, heat to 130 °C and stir for 12 hours. After the reaction is basically complete as detected by LC-MS, add ethyl acetate (10 mL) and water (10 mL) to the mixture, stir, separate the layers, extract the aqueous phase with ethyl acetate (10 mL), and combine the organic phases. Wash successively with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (10 mL), dry with anhydrous sodium sulfate, filter, and concentrate to obtain a brown oily substance (68 mg, yield: 17.5%).

[0120] ESI-MS m / z: 316 [M+H] +

[0121] Step 9: Synthesis of Compound 3:

[0122]

[0123] Add int_3-11 (5.7 mg, 0.17 mmol), DMF (5 mL), DIPEA (66 mg, 0.5 mmol), HATU (100 mg, 0.34 mmol), and int_1-5 (97 mg, 0.34 mmol) to a 50 mL single-necked flask. After purging the mixture with argon, heat to 60 °C and stir for 4 hours. After the reaction was basically complete as detected by LC-MS, the mixture was purified by preparative LC-MS to obtain the product (20 mg, yield: 41.5%, white solid).

[0124] 1 H NMR (400MHz, DMSO-d6) δ11.97(s,1H),8.97(s,1H),8.63(d,J=5.5Hz,1H),8.4 2(d,J=9.1Hz,1H),8.34(d,J=2.9Hz,1H),7.86(dd,J=9.0,2.9Hz,1H),7.69–7. 57(m,3H),7.46(dd,J=7.0,1.8Hz,2H),7.37(d,J=1.7Hz,1H),6.69(d,J=5.5H z,1H),4.00(s,3H),3.91(s,3H),2.53(d,J=5.9Hz,4H),1.98(p,J=6.1Hz,2H).

[0125] ESI-MS m / z: 581 [M+H] +

[0126] Example 4: Synthesis of Compound 4

[0127]

[0128] Step 1: Synthesis of compound int_4-2:

[0129]

[0130] Int_4-1 (210 mg, 0.86 mmol), DMF (5 mL), DIPEA (1.5 mL), and 6-nitropyridine-3-ol (121 mg, 0.86 mmol) were added to a 50 mL single-necked flask. After purging the mixture with argon, the temperature was raised to 100 °C and stirred for 72 h. After the reaction was basically complete as detected by LC-MS, ethyl acetate (10 mL) and water (10 mL) were added to the mixture, stirred, and separated. The aqueous phase was extracted again with ethyl acetate (10 mL). The combined organic phases were washed successively with saturated sodium bicarbonate solution (10 mL) and saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain an oily substance (198 mg, yield: 68%).

[0131] ESI-MS m / z: 346 [M+H] +

[0132] Step 2: Synthesis of compound int_4-3:

[0133]

[0134] Int_4-2 (198 mg, 0.57 mmol), MeOH (10 mL), DCM (1 mL), and 10% palladium on carbon (50 mg, wet = 55%) were added to a 100 mL single-necked flask. After three purgings with hydrogen, the mixture was stirred at room temperature and atmospheric pressure for hydrogenation. After 72 h, LC-MS analysis showed that the reaction was complete. The mixture was filtered with diatomaceous earth as an aid, and the filtrate was concentrated to obtain the product (180 mg, yield: 100%).

[0135] ESI-MS m / z: 316 [M+H] +

[0136] Step 4: Synthesis of Compound 4:

[0137]

[0138] Add int_4-3 (100 mg, 0.317 mmol), DMF (5 mL), DIPEA (114 mg, 0.885 mmol), HATU (170 mg, 0.442 mmol), and int_1-5 (84 mg, 0.295 mmol) to a 50 mL single-necked flask. After purging the mixture with argon, heat to 60 °C and stir for 4 h. After the reaction was basically complete as detected by LC-MS, the mixture was purified by preparative LC-MS to obtain the product (29 mg, yield: 15.8%).

[0139] ESI-MS m / z: 581 [M+H] +

[0140] Example 5: In vitro inhibition assay of Axl enzyme activity by the compound of the present invention.

[0141] The compound was serially diluted with DMSO and mixed with Axl or c-Met recombinant protein. After incubation at room temperature for 10 minutes, biotin-labeled TK substrate (TK) and ATP were added. After reacting at room temperature for 40 minutes, Sa-XL 665 and Cryptotate-labeled TK antibody were added. After incubation at room temperature for 1 hour, the fluorescence intensity at 615 and 665 nm was measured. The ratio of fluorescence intensity at 665 nm to 615 nm was calculated. The IC50 of the compound was calculated compared with the DMSO control group. 50 The results are shown in Table 1 below.

[0142] Table 1. Inhibitory activity of the compounds of the present invention against recombinant protein Axl

[0143] compound <![CDATA[Axl enzyme activity inhibition (IC 50 , nM)]]> <![CDATA[c-Met enzyme activity inhibition (IC 50 , nM)]]> 1 0.8 5.49 2 +++ - 3 +++ - 4 +++ - Compound A 1.1 13.35

[0144] +++ indicates IC 50 Less than or equal to 50 nM

[0145] ++ indicates IC 50 50 nM to 100 nM

[0146] + indicates IC 50 Greater than 100 nM.

[0147] - Indicates activity not measured

[0148] As shown in Table 1, the compounds of this invention exhibit good inhibitory activity against the recombinant protein Axl. Furthermore, compared to compound A, compound 1 shows an unexpectedly enhanced inhibitory activity against c-Met enzyme.

[0149] Example 6: In vitro antiproliferative activity of the compounds of the present invention against BaF3-Axl cells

[0150] 10,000 BaF3 (BaF3-Axl) cells overexpressing Axl were seeded per well in 96-well plates, followed by treatment with a compound serially diluted in DMSO. After 3 days of treatment, intracellular ATP levels were measured using CTL-PLUS. The percentage of cell growth inhibition and IC50 were calculated compared to the DMSO group. 50 The results are shown in Table 2 below.

[0151] Table 2. Antiproliferative activity of the compounds of the present invention against BaF3-Axl cells.

[0152] compound <![CDATA[BaF3-Axl cell anti-proliferative activity IC 50 (nM)]]> 1 0.5 2 3.5 3 5 4 >5 Compound A 1.2

[0153] As shown in Table 2, the compounds of this invention all exhibit strong anti-proliferative activity against BaF3 / Axl cells, but compounds 2 and 3 show weaker anti-proliferative activity against BaF3 / Axl cells than compound 1. This result indicates that the position of the fluorine atom substitution in compounds 1, 2, and 3 has an unexpected effect on the activity of the compounds. Furthermore, compared with compound A, compound 1 shows an unexpectedly enhanced anti-BaF3 / Axl proliferation activity.

[0154] Example 7: In vivo pharmacokinetic experiments of the compounds of the present invention

[0155] Female CD-1 mice aged 7 to 10 weeks were selected, and the intravenous and oral doses were 2 mg / kg and 10 mg / kg, respectively. Mice were fasted for at least 12 hours before administration, and food was provided 4 hours after administration. Water was available freely throughout the experiment. On the day of the experiment, animals in the intravenous group received a single injection of the corresponding compound via the tail vein, with a dosage volume of 10 ml / kg. Animals in the oral group received a single injection of the corresponding compound via gavage, with a dosage volume of 10 ml / kg. Animal weight was measured before administration, and the dosage volume was calculated based on body weight. Sample collection times were: 0.083 (injection group), 0.167, 0.5, 1, 2, 4, 8, and 24 hours. Approximately 200 μL of whole blood was collected from the submandibular venous plexus at each time point to prepare plasma for high-performance liquid chromatography-tandem mass spectrometry (LC-MS / MS) concentration determination. All animals were euthanized under CO2 anesthesia after the last time point PK sample was collected. Phoenix WinNonlin was used. TM The non-compartmental model of the Certara pharmacokinetic software version 8.3 was used to process plasma concentrations, and the linear logarithmic trapezoidal method was used to calculate pharmacokinetic parameters. The in vivo pharmacokinetic results are shown in Table 3 below.

[0156] Table 3. In vivo pharmacokinetic evaluation results of the compounds of this invention.

[0157]

[0158] As shown in Table 3, in the mouse pharmacokinetic experiments, compared with compound A, compound 1 of this invention exhibited increased Vdss, decreased in vivo clearance, prolonged half-life, and increased AUC. Compared with compound A, compound 1 showed unexpected improvements in pharmacokinetic properties.

[0159] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. A compound as shown in formula (1) or a pharmaceutically acceptable salt thereof: 。 2. A pharmaceutical composition, characterized in that, It contains a pharmaceutically acceptable excipient or carrier, and the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof as the active ingredient.

3. The use of a compound as described in claim 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 2, in the preparation of a medicament for treating diseases related to Axl protein.

Citation Information

Patent Citations

  • Quinoline derivative

    WO2015012298A1

  • Quinoline derivative

    CN105408312A

  • Quinoline derivative

    US20170349583A1